Pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and/or salt thereof for improving liver functioning

Abstract

A method of treating a patient to improve liver functioning includes providing a drug composed of at least one of pharmaceutical 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and a salt thereof; and administering the drug to the patient in a manner and dosage effective to improve liver functioning. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including MMPs and TIMPs, and so it can inhibit liver fibrosis. In the liver, it can inhibit collagen synthesis and expression, and therefore reverse and treat hepatitis and liver cirrhosis effectively. Also disclosed is a method for preparing drugs for treating infective hepatitis, non-infectious hepatitis, liver injury, liver cirrhosis, liver cancer and liver fibrosis, and improving t liver functioning, in which the compound and/or salt thereof is used optionally or in combination with a target molecule or carrier comprising a vitamin A-coupled liposome.

What is claimed is: 
     
         1 . A pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and salt thereof for preparing drugs for treating or preventing non-infectious hepatitis. 
     
     
         2 . A pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and salt thereof for preparing drugs for treating or preventing liver injury. 
     
     
         3 . A pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and salt thereof for preparing drugs for protecting and improving the liver function. 
     
     
         4 . A pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and salt thereof, or use in combination with a target molecule or carrier comprising a vitamin A-coupled liposome, for preparing drugs for treating or preventing infective hepatitis, non-infectious hepatitis, liver injury, liver cirrhosis, liver cancer and liver fibrosis, thus protecting and improving the liver function. 
     
     
         5 . A method of treating a patient to improve liver functioning, comprising:
 providing a drug comprised of at least one of pharmaceutical 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and a salt thereof; and   administering the drug to the patient in a manner and dosage effective to improve liver functioning.   
     
     
         6 . The method according to  claim 5  applied to treating a patient for liver cirrhosis to improve liver functioning, comprising:
 providing a drug comprised of at least one of pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and a salt thereof; and 
 administering the drug to the patient in a manner and dosage effective to treat liver cirrhosis. 
 
     
     
         7 . The method according to  claim 5  applied to treating a patient for liver cancer to improve liver functioning, comprising:
 providing a drug comprised of at least one of pharmaceutical 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and a salt thereof; and 
 administering the drug to the patient in a manner and dosage effective to treat liver cancer. 
 
     
     
         8 . The method according to  claim 5  applied to treating a patient for at least one of infective hepatitis, non-infectious hepatitis, liver injury, liver cirrhosis, and liver cancer to improve liver functioning, comprising:
 providing a drug comprised of at least one of pharmaceutical 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and a salt thereof; and optionally a target molecule or carrier comprising a vitamin A-coupled liposome; and 
 administering the drug to the patient in a manner and dosage effective to improve liver functioning. 
 
     
     
         9 . The method according to  claim 5 , wherein the drug comprises at least one of pharmaceutical 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and a salt thereof; and a target molecule or carrier comprising a vitamin A-coupled liposome.